Trial Profile
A trial to examine the impact of natalizumab (NTZ) dose variability on serum levels and VLA-4 receptor occupancy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 May 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics; Pharmacokinetics
- 10 May 2016 New trial record
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology